February 6, 2019 08:22 AM EST

Capricor to resume dosing in DMD trial — but scarce resources force company to pause enrollment, cut jobs

Natalie Grover

Reporter

Little Capricor $CAPR is doing its best to limit the damage of its big problems. On Wednesday, the company said it is exploring strategic alternatives …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Capricor to resume dosing in DMD trial — but scarce resources force company to pause enrollment, cut jobs

Natalie Grover

Reporter

Sign up to read this article for free.

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Ozempic makes list for next round of Medicare drug price negotiations

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Capri­cor to re­sume dos­ing in DMD tri­al — but scarce re­sources force com­pa­ny to pause en­roll­ment, cut jobs

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Capricor to resume dosing in DMD trial — but scarce resources force company to pause enrollment, cut jobs

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Ozempic makes list for next round of Medicare drug price negotiations

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down